ST
Starling Oncology, Inc.
STLN · NASDAQ
$6.43 -2.28% (-$0.15)
1M +1.74%
Market Cap $642.9M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$4.2
34.7% downside
Current Price
$6.43
Undervalued Fair Value Overvalued
According to Bulios Fair Price, STLN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 1.09x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Rev. growth 25.81%
EPS growth N/A
Book val. growth N/A
Profitability
5 /100
Weak Gross margin 15.69%
FCF margin 0.56%
Net margin 6.18%
Quality
21 /100
Poor ROIC 28.82%
Asset turnover 3.29x
ROA 20.36%
Debt
27 /100
High Current ratio 1.36x
Int. coverage -3.76x
Debt/Equity N/A
Stability
46 /100
Moderate Beta 0.44x
Profitable years 0
Rev. volatility 3.92%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about STLN
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Daniel Virnich
Employees
641
Headquarters
Cerritos